Molecularly Aided Stratification for Tumor Eradication Research

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

NCT/DKFZ/DKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive molecular profiling, and clinical decision-making in a multidisciplinary molecular tumor board.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04504604` - TCF-001 TRACK (Target Rare Cancer Knowledge) Study	N/A
Active, not recruiting	`NCT01505400` - Integrated Molecular Profiling in Advanced Cancers Trial
Recruiting	`NCT03340506` - Dabrafenib and/or Trametinib Rollover Study	Phase 4

NCT number	NCT05852522
Study type	Observational [Patient Registry]
Source	German Cancer Research Center
Contact	Richard F Schlenk, M.D.
Phone	+49 6221
Email	richard.schlenk@nct-heidelberg.de
Status	Recruiting
Phase
Start date	November 11, 2018
Completion date	October 2029

Molecularly Aided Stratification for Tumor Eradication Research — NCT-MASTER

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms